Supercritical Carbon Dioxide Extracts of Cordyceps sinensis: Chromatography-based Metabolite Profiling and Protective Efficacy Against Hypobaric Hypoxia

Cordyceps: Alleviating ischemic cardiovascular and cerebrovascular injury - A comprehensive review

ETHNOPHARMACOLOGICAL RELEVANCE

Cordyceps has a long medicinal history as a nourishing herb in traditional Chinese medicine (TCM). Ischemic cardio-cerebrovascular diseases (CCVDs), including cerebral ischemic/reperfusion injury (CI/RI) and myocardial ischemic/reperfusion injury (MI/RI), are major contributors to mortality and disability in humans. Numerous studies have indicated that Cordyceps or its artificial substitutes have significant bioactivity on ischemic CCVDs, however, there is a lack of relevant reviews.

AIM OF THE STUDY

This review was conducted to investigate the chemical elements, pharmacological effects, clinical application and drug safety of Cordycepson ischemic CCVDs.

MATERIALS AND METHODS

A comprehensive search was conducted on the Web of Science, PubMed, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases using the keywords "Cordyceps", "Cerebral ischemic/reperfusion injury", and "Myocardial ischemic/reperfusion injury" or their synonyms. The retrieved literature was then categorized and summarized.

RESULTS

The study findings indicated that Cordyceps and its bioactive components, including adenosine, cordycepin, mannitol, polysaccharide, and protein, have the potential to protect against CI/RI and MI/RI by improving blood perfusion, mitigating damage from reactive oxygen species, suppressing inflammation, preventing cellular apoptosis, and promoting tissue regeneration. Individually, Cordyceps could reduce neuronal excitatory toxicity and blood-brain barrier damage caused by cerebral ischemia. It can also significantly improve cardiac energy metabolism disorders and inhibit calcium overload caused by myocardial ischemia. Additionally, Cordyceps exerts a significant preventive or curative influence on the factors responsible for heart/brain ischemia, including hypertension, thrombosis, atherosclerosis, and arrhythmia.

CONCLUSION

This study demonstrates Cordyceps' prospective efficacy and safety in the prevention or treatment of CI/RI and MI/RI, providing novel insights for managing ischemic CCVDs.

An authentic assessment method for cordyceps sinensis

Cordyceps Sinensis, renowned for its diverse pharmacological properties and the rarity of its natural species, faces significant challenges due to rampant adulteration by counterfeit products. Consequently, there is a crucial need to reliably identify Cordyceps species to ensure their quality and efficacy. While current analytical techniques predominantly rely on LC-MS, there remains a notable deficiency and substantial demand for the development of a unified, reproducible, and fast method suitable for commercial applications. In this study, we employed a cost-effective and straightforward approach utilizing headspace GC-MS to authenticate Cordyceps sinensis. This method enables the comprehensive analysis of the chemical profile, facilitating the identification of quality and authenticity in Cordyceps samples. Through a comparative analysis of the chemical profiles of seven authentic Cordyceps samples with seven other Cordyceps samples, we propose a Quality Assessment System for Authentic Cordyceps, encompassing the following criteria: 1) the presence of 29 compounds commonly found in authentic Cordyceps within the chemical profile, and 2) the area ratio of 3-methylbutanal to 2-methylbutanal falling within the range of 2.09-3.01. This method exhibits considerable promise as a standardized, reproducible, and expeditious technique for the quality assessment and authentication of Cordyceps.